Lulizumab pegol

Drug Profile

Lulizumab pegol

Alternative Names: BMS-931699; Lulizumab

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Bristol-Myers Squibb
  • Class Monoclonal antibodies; Polyethylene glycols
  • Mechanism of Action CD28 antigen modulators; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Sjogren's syndrome; Systemic lupus erythematosus

Most Recent Events

  • 01 Oct 2016 Phase-II clinical trials in Sjogren's syndrome in USA (SC) (NCT02843659)
  • 21 Jul 2016 Bristol-Myers Squibb plans a phase II trial for Sjögren's syndrome in Australia, Chile, Hungary, Mexico, Poland, Puerto Rico, Russia and South Africa and USA (SC, Injection) (NCT02843659)
  • 08 Jul 2016 Preclinical trials in Sjogren's syndrome in USA (SC) before July 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top